AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04098562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Wound Care
Description: Standard wound debridement
Study NCT02773173 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPP in colorectal laparoscopic surgery
Description: Deep neuromuscular blockade can only be reversed with sugammadex, so in the IPP group, it will be used as neuromuscular blocking agent and its effect will be reversed with sugammadex (4mg / kg) at the end of the surgery. During surgery: deep neuromuscular blockade (PTC 1-5), Protective ventilation strategy, Optimal position and Pre stretching as a tool to decrease intraabdominal pressure maintaining optimal workspace.
Study NCT02773173 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: SPP in colorectal laparoscopic surgery
Description: A depolarizing neuromuscular blocking will be used (as routine clinical practice at each center) to maintain moderate neuromuscular blockade and its effect will be reversed with anticholinesterase at the end of the surgery. During surgery: Moderate neuromuscular blockade ( TOF 2-4) , position to surgeon criteria, no prestretching and Protective ventilation. Fixed IAP (12mmHg).
Study NCT03117998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REMD-477
Description: Administered as repeated SC doses in subjects with Type 1 Diabetes
Study NCT03117998 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Administered as a repeated SC doses in subjects with Type 1 Diabetes
Study NCT03298477 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nellix® System
Description: Endovascular Abdominal Aortic Aneurysm Repair using the Nellix® System
Study NCT02870829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: menaquinone-7
Description: Oral supplement given post dialysis 3x/week
Study NCT00293059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
Description: 2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
Study NCT00293059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be taken orally daily.
Study NCT00970762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg intubating dose
Description: Rocuronium 0.6 mg/kg intubating dose
Study NCT00970762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg intubating dose
Description: 0.9 mg/kg intubating dose of rocuronium
Study NCT00970762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.1 mg/kg maintenance dose
Description: Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
Study NCT00970762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.15 mg/kg maintenance dose
Description: Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
Study NCT00970762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.2 mg/kg maintenance
Description: Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
Study NCT00970762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium 0.1 mg/kg intubating dose
Description: Vecuronium 0.1 mg/kg intubating dose
Study NCT00970762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium 0.025 mg/kg maintenance dose
Description: Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
Study NCT03287895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support
Description: A two-part intervention to help patients make better decisions about CPR
Study NCT02001064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care4Today v2.0 mobile application + electronic monitoring of adherence
Description: Care4Today mobile application will send automated medication alert messages to HIV-infected persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV-infected persons who experience adherence difficulties over standard of care.
Study NCT04188275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Periodic ARV7 and miRNA evaluation
Description: Determination of AR-V7 splice variants on circulating tumor cells and evaluation of circulating levels of miRNA by blood sample collection during PSA assessment at different time points along the treatment course (initiation, 8-weeks assessment, progression).
Study NCT01390870 — intervention group
Intervention type: DRUG
Intervention: 5ARI or AB or Combination Therapy (5ARI + AB)
Description: 5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
Study NCT04050657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: appointment interval
Description: To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances
Study NCT04050657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: appointment interval
Description: To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances
Study NCT02498912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Production of Genetically-modified T cells
Study NCT02498912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02498912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IP Catheter Insertion
Study NCT02498912 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells
Description: Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.
Study NCT02498912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: fludarabine dose 25-30 mg/m2 x 3 days
Study NCT00501280 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview by telephone or on-site in language of choice (English or Spanish), 60 to 70 minutes to complete the mother's and the child participants' questionnaires
Study NCT04469049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Description: MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
Study NCT03932305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lutein
Description: Lutein is a common oral supplement that may have neuroprotective effect on the human retina
Study NCT03932305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo tablet
Study NCT01809834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etafilcon A
Study NCT01809834 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenfilcon A
Study NCT00422812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Inhaled Staccato Placebo
Study NCT00422812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PCZ 5 mg
Description: Inhaled Staccato Prochlorperazine 5 mg
Study NCT00422812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PCZ 7.5 mg
Description: Inhaled Staccato Prochlorperazine 7.5 mg
Study NCT00422812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PCZ 10 mg
Description: Inhaled Staccato Prochlorperazine 10 mg
Study NCT01519505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: INDIVIDUAL INTERVENTIONS They were programmed to come the nurse office three times (1 ½ -2 hours each). Individual intervention efforts outside of weight control and other intervention groups were also supported. In fact, this kind of intervention was similar to the group intervention but one-by-one participant subject. GROUP INTERVENTIONS Six-hour educational programme structured in 2 to 4 sessions with 5 to 15 participants. We called all participants to remind them their group schedule (date/hour). The methods used in the group intervention were variable depending on the experience of the manager, group member' s needs and skills available (empowerment). Results were based on motivation, support from the other members, peer support and positive feedback.
Study NCT01397422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADS-5102 (extended release amantadine HCl)
Description: Oral capsules to be administered once daily at bedtime, for 8 weeks
Study NCT01397422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADS-5102 (extended release amantadine HCl)
Description: Oral capsules to be administered once daily at bedtime, for 8 weeks
Study NCT02622529 — intervention group
Intervention type: OTHER
Intervention: Screening through questionnaires
Description: Distribution of Questionnaires to every participant within the single existent Arm at three times.
Study NCT04127500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine
Study NCT02893787 — intervention group
Intervention type: OTHER
Intervention: Speckle Tracking Echocardiography
Description: Echocardiography analyses
Study NCT00072137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-TRICOM Vaccine
Description: Given intravesically
Study NCT00072137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox GM-CSF Vaccine Adjuvant
Description: Given intravesically
Study NCT00072137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo cystectomy
Study NCT00072137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00072137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03613376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Class II compression stockings
Description: Patients in this group will use class II compression stocking continuously until next evening and then next 4 days during daytime
Study NCT02284217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVD
Description: ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.
Study NCT01307683 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful Moms
Description: 8 weekly 2-hour sessions, 2 booster telephone sessions, and 1 postpartum booster session
Study NCT02539745 — intervention group
Intervention type: OTHER
Intervention: Vitamin D receptor polymorphic analysis
Description: Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
Study NCT02539745 — intervention group
Intervention type: OTHER
Intervention: Serum levels of 1a, 25-Dihydroxyvitamin D3
Description: Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
Study NCT03193775 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBV vaccine
Description: HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).
Study NCT03698110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: PUEDES program included eight hours in groups and activities to practice at home.
Study NCT01282853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic biopsy
Description: endoscopic biopsy for rapid urease test
Study NCT01282853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic biopsy
Description: endoscopic biopsy for rapid urease test
Study NCT01986452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Study NCT01986452 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP therapy
Study NCT01986452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support
Study NCT03698526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Samsung Gear VR, Galaxy S8, Applied VR App
Description: Virtual Reality Experience
Study NCT00353249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted cognitive behavioral therapy (CBT)
Description: Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
Study NCT04613583 — intervention group
Intervention type: OTHER
Intervention: SAFeR fetuses
Description: NO active intervention performed.
Study NCT03547973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously.
Study NCT03547973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered per package insert
Study NCT03547973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered per package insert
Study NCT03547973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administered per package insert
Study NCT03547973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously
Study NCT03547973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered per package insert
Study NCT03547973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered per package insert
Study NCT03547973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Administered intravenously
Study NCT03547973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Administered intravenously
Study NCT03122691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis
Description: Cannabis will be self-administered by study participants
Study NCT02517801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin capsules
Description: Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.
Study NCT02517801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.
Study NCT01428505 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: [18F]PBR111
Description: radioligand to assess binding to TSPO
Study NCT04302948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCV RNA screening
Description: The Cepheid Xpert testing requires a fingerstick to obtain blood spots which are then tested for HCV RNA. Results available within one to two hours, facilitating counseling for patients to link to care.
Study NCT00108732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given orally
Study NCT00108732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT00108732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
Description: Given SC
Study NCT00108732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia-TRICOM Vaccine
Description: Given SC
Study NCT00108732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT02576509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days
Study NCT02576509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Specified Dose on Specified Days
Study NCT02237183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Given via inhalation
Study NCT02237183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given via inhalation
Study NCT02237183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02237183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02237183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02237183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00458302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir (DRV, TMC114)
Description: 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
Study NCT00458302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir (DRV, TMC114)
Description: 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
Study NCT04591626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study NCT04591626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04591626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC
Study NCT01711697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT
Study NCT01711697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT01711697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01711697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT01720641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet
Description: Referral and user instructions for Peru section of www.inspot.org partner notification website
Study NCT01720641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral Card
Description: 5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources.
Study NCT01720641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet and Referral Card
Description: 5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources; Referral and user instructions for Peru section of www.inspot.org partner notification website.
Study NCT04362124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine BCG
Description: Performance evaluation of a single dose of BCG vaccine in reducing the severity of SARS-COV-2 infection compared to placebo, in healthcare personnel.
Study NCT04362124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose intradermal application of normal saline solution.
Study NCT04132037 — intervention group
Intervention type: OTHER
Intervention: data record
Description: At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported
Study NCT00303030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1. Anal injection
Description: Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
Study NCT00303030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2. Biofeedback
Description: Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
Study NCT00193375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2 days 1 \& 8 each 21-day cycle 1 \& 2, 28-day cycle 3 \& 4
Study NCT00193375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5
Study NCT00193375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg IV every 2 weeks for 10 doses starting week 16
Study NCT00193375 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT00072384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal vincristine sulfate
Description: Given IV
Study NCT00072384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery
Description: Application of extreme cold to destroy abnormal or diseased tissue.
Study NCT00072384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser surgery
Description: Surgery using a laser (instead of a scalpel) to cut tissue